ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Evaluate the Neurological Effects of EryDex on Subjects With A-T

ClinicalTrials.gov ID: NCT06193200

Public ClinicalTrials.gov record NCT06193200. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on Subjects With Ataxia Telangiectasia (NEAT)

Study identification

NCT ID
NCT06193200
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Enrollment
105 participants

Conditions and interventions

Interventions

  • Dexamethasone sodium phosphate Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
6 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 23, 2024
Primary completion
Dec 16, 2025
Completion
Dec 16, 2025
Last update posted
Apr 29, 2026

2024 – 2025

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence Los Angeles California 90095
The Johns Hopkins Hospital, Division of pediatric allergy and immunology Baltimore Maryland 21289
Cincinnati Children's Hospital, Division of neurology Cincinnati Ohio 45229
UT Health Houston, Department of pediatrics, division of child & adolescent neurology Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06193200, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 29, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06193200 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →